SCHEMBL6208936

SCHEMBL6208936

N#CC1(c2ccc(OCc3ccccc3)cc2)CCCCC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.54
RORC P51449 1/20 0.48
FFAR4 Q5NUL3 3/20 0.47
OPRM1 P35372 1/20 0.47
LMNA P02545 5/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
CYP1A2 P05177 1/20 0.46
PTGS1 P23219 1/20 0.46
SLC6A2 P23975 1/20 0.46
CYP2C19 P33261 1/20 0.46
PTGS2 P35354 1/20 0.46
SLC6A3 Q01959 1/20 0.46
HIF1A Q16665 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
RAB9A P51151 2/20 0.45
GAA P10253 1/20 0.45
MAPT P10636 1/20 0.45
MAOA P21397 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
MEN1 O00255 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6211633 0.99 MAOB (0.55) MAOBRORCFFAR4OPRM1LMNA
SCHEMBL2277113 0.96 MAOB (0.55) MAOBRORCFFAR4OPRM1LMNA
SCHEMBL6208176 0.93 MAOB (0.58) MAOBFFAR4OPRM1LMNASMN1; SMN2
SCHEMBL9966478 0.86 MAOB (0.51) MAOBFFAR4OPRM1LMNASMN1; SMN2
SCHEMBL21874085 0.86 MAOB (0.51) MAOBRORCFFAR4OPRM1LMNA
SCHEMBL11044387 0.85 MAOB (0.50) MAOBRORCFFAR4OPRM1LMNA
SCHEMBL11059742 0.83 MAOB (0.48) MAOBFFAR4OPRM1LMNASMN1; SMN2
SCHEMBL2274605 0.82 LMNA (0.51) MAOBFFAR4LMNASMN1; SMN2RAB9A
SCHEMBL17072362 0.78 LMNA (0.54) MAOBRORCLMNASMN1; SMN2CYP1A2
SCHEMBL10041856 0.78 LMNA (0.54) MAOBRORCLMNASMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050234096-A1 Tetrahydroisoquinoline derivatives BAYER HEALTHCARE AG (DE) 2005-10-20 US disclosed
EP-1507763-A1 TETRAHYDROISOQUINOLINE DERIVATIVES Bayer HealthCare AG (DE) 2005-02-23 EP disclosed
WO-2003097607-A1 TETRAHYDROISOQUINOLINE DERIVATIVES BAYER HEALTHCARE AG (DE) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234096-A1 Tetrahydroisoquinoline derivatives PPARD, PPARG, PPARA MAOB 3628/4885RORC 81/4885FFAR4 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.